Zynex, Inc. (NASDAQ:ZYXI) CEO Sells $17,340.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $8.67, for a total transaction of $17,340.00. Following the sale, the chief executive officer now directly owns 14,619,350 shares of the company’s stock, valued at $126,749,764.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Trading Up 2.0 %

Zynex stock opened at $9.01 on Friday. The firm has a 50 day moving average of $8.18 and a 200 day moving average of $8.98. The firm has a market capitalization of $286.97 million, a price-to-earnings ratio of 60.07 and a beta of 0.53. Zynex, Inc. has a 12-month low of $7.15 and a 12-month high of $13.77. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last released its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. As a group, research analysts predict that Zynex, Inc. will post 0.2 earnings per share for the current year.

Institutional Investors Weigh In On Zynex

A number of institutional investors have recently added to or reduced their stakes in ZYXI. LSV Asset Management grew its holdings in Zynex by 45.1% during the 1st quarter. LSV Asset Management now owns 108,935 shares of the company’s stock valued at $1,348,000 after buying an additional 33,840 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in Zynex during the 1st quarter valued at approximately $137,000. Vanguard Group Inc. grew its holdings in Zynex by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock valued at $14,684,000 after buying an additional 6,097 shares in the last quarter. BOKF NA purchased a new stake in Zynex during the 1st quarter valued at approximately $246,000. Finally, Hancock Whitney Corp grew its holdings in Zynex by 24.9% during the 1st quarter. Hancock Whitney Corp now owns 32,903 shares of the company’s stock valued at $407,000 after buying an additional 6,566 shares in the last quarter. 29.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on ZYXI. HC Wainwright upped their price target on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada reduced their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.